Loading…

CCL20 blockade increases the severity of nephrotoxic folic acid‐induced acute kidney injury

The chemokine CCL20 activates the CCR6 receptor and has been implicated in the pathogenesis of glomerular injury. However, it is unknown whether it contributes to acute kidney injury (AKI). We identified CCL20 as upregulated in a systems biology strategy combining transcriptomics of kidney tissue fr...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of pathology 2018-10, Vol.246 (2), p.191-204
Main Authors: González‐Guerrero, Cristian, Morgado‐Pascual, José Luis, Cannata‐Ortiz, Pablo, Ramos‐Barron, María Angeles, Gómez‐Alamillo, Carlos, Arias, Manuel, Mezzano, Sergio, Egido, Jesús, Ruiz‐Ortega, Marta, Ortiz, Alberto, Ramos, Adrián M
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3532-d35790560619293b1411b08fd9fe87ce9bca56b7b60212a6dd733a401c8230b93
cites cdi_FETCH-LOGICAL-c3532-d35790560619293b1411b08fd9fe87ce9bca56b7b60212a6dd733a401c8230b93
container_end_page 204
container_issue 2
container_start_page 191
container_title The Journal of pathology
container_volume 246
creator González‐Guerrero, Cristian
Morgado‐Pascual, José Luis
Cannata‐Ortiz, Pablo
Ramos‐Barron, María Angeles
Gómez‐Alamillo, Carlos
Arias, Manuel
Mezzano, Sergio
Egido, Jesús
Ruiz‐Ortega, Marta
Ortiz, Alberto
Ramos, Adrián M
description The chemokine CCL20 activates the CCR6 receptor and has been implicated in the pathogenesis of glomerular injury. However, it is unknown whether it contributes to acute kidney injury (AKI). We identified CCL20 as upregulated in a systems biology strategy combining transcriptomics of kidney tissue from experimental toxic folic acid‐induced AKI and from stressed cultured tubular cells and have explored the expression and function of CCL20 in experimental and clinical AKI. CCL20 upregulation was confirmed in three models of kidney injury induced by a folic acid overdose, cisplatin or unilateral ureteral obstruction. In injured kidneys, CCL20 was expressed by tubular, endothelial, and interstitial cells, and was also upregulated in human kidneys with AKI. Urinary CCL20 was increased in human AKI and was associated with severity. The function of CCL20 in nephrotoxic folic acid‐induced AKI was assessed by using neutralising anti‐CCL20 antibodies or CCR6‐deficient mice. CCL20/CCR6 targeting increased the severity of kidney failure and mortality. This was associated with more severe histological injury, nephrocalcinosis, capillary rarefaction, and fibrosis, as well as higher expression of tubular injury‐associated genes. Surprisingly, mice with CCL20 blockade had a lower tubular proliferative response and a higher number of cells in the G2/M phase, suggesting impaired repair mechanisms. This may be related to a lower influx of Tregs, despite a milder inflammatory response in terms of chemokine expression and infiltration by IL‐17+ cells and neutrophils. In conclusion, CCL20 has a nephroprotective role during AKI, both by decreasing tissue injury and by facilitating repair. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
doi_str_mv 10.1002/path.5132
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2110260205</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2110260205</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3532-d35790560619293b1411b08fd9fe87ce9bca56b7b60212a6dd733a401c8230b93</originalsourceid><addsrcrecordid>eNp1kL9OwzAQhy0EoqUw8AIoEhNDytnOP49VBRSpEgxlRJFjX9S0aRLsBMjGI_CMPAkuLWwsdzrdd99JP0LOKYwpALtuZLsch5SzAzKkICJfJCI6JEO3Yz4PaDwgJ9auAECIMDwmAyZEEgTAh-R5Op0z8LKyVmup0SsqZVBatF67RM_iK5qi7b069ypslqZu6_dCeXlduipVob8-PotKdwq1G7sWvXWhK-ydZ9WZ_pQc5bK0eLbvI_J0e7OYzvz5w939dDL3FQ858zUPYwFhBBEVTPCMBpRmkORa5JjECkWmZBhlcRYBo0xGWsecywCoShiHTPARudx5G1O_dGjbdFV3pnIvU0YpMHcHoaOudpQytbUG87QxxUaaPqWQboNMt0Gm2yAde7E3dtkG9R_5m5wDrnfAW1Fi_78pfZwsZj_Kb3xLfTo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2110260205</pqid></control><display><type>article</type><title>CCL20 blockade increases the severity of nephrotoxic folic acid‐induced acute kidney injury</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>González‐Guerrero, Cristian ; Morgado‐Pascual, José Luis ; Cannata‐Ortiz, Pablo ; Ramos‐Barron, María Angeles ; Gómez‐Alamillo, Carlos ; Arias, Manuel ; Mezzano, Sergio ; Egido, Jesús ; Ruiz‐Ortega, Marta ; Ortiz, Alberto ; Ramos, Adrián M</creator><creatorcontrib>González‐Guerrero, Cristian ; Morgado‐Pascual, José Luis ; Cannata‐Ortiz, Pablo ; Ramos‐Barron, María Angeles ; Gómez‐Alamillo, Carlos ; Arias, Manuel ; Mezzano, Sergio ; Egido, Jesús ; Ruiz‐Ortega, Marta ; Ortiz, Alberto ; Ramos, Adrián M</creatorcontrib><description>The chemokine CCL20 activates the CCR6 receptor and has been implicated in the pathogenesis of glomerular injury. However, it is unknown whether it contributes to acute kidney injury (AKI). We identified CCL20 as upregulated in a systems biology strategy combining transcriptomics of kidney tissue from experimental toxic folic acid‐induced AKI and from stressed cultured tubular cells and have explored the expression and function of CCL20 in experimental and clinical AKI. CCL20 upregulation was confirmed in three models of kidney injury induced by a folic acid overdose, cisplatin or unilateral ureteral obstruction. In injured kidneys, CCL20 was expressed by tubular, endothelial, and interstitial cells, and was also upregulated in human kidneys with AKI. Urinary CCL20 was increased in human AKI and was associated with severity. The function of CCL20 in nephrotoxic folic acid‐induced AKI was assessed by using neutralising anti‐CCL20 antibodies or CCR6‐deficient mice. CCL20/CCR6 targeting increased the severity of kidney failure and mortality. This was associated with more severe histological injury, nephrocalcinosis, capillary rarefaction, and fibrosis, as well as higher expression of tubular injury‐associated genes. Surprisingly, mice with CCL20 blockade had a lower tubular proliferative response and a higher number of cells in the G2/M phase, suggesting impaired repair mechanisms. This may be related to a lower influx of Tregs, despite a milder inflammatory response in terms of chemokine expression and infiltration by IL‐17+ cells and neutrophils. In conclusion, CCL20 has a nephroprotective role during AKI, both by decreasing tissue injury and by facilitating repair. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley &amp; Sons, Ltd.</description><identifier>ISSN: 0022-3417</identifier><identifier>EISSN: 1096-9896</identifier><identifier>DOI: 10.1002/path.5132</identifier><identifier>PMID: 29984403</identifier><language>eng</language><publisher>Chichester, UK: John Wiley &amp; Sons, Ltd</publisher><subject>Acids ; acute kidney injury ; Animal models ; calcification ; Calcinosis ; CCL20 ; CCL20 protein ; CCR6 ; CCR6 protein ; chemokine ; Chemokines ; Cisplatin ; Fibrosis ; Folic acid ; Inflammation ; Inflammatory response ; Interstitial cells ; Kidney diseases ; Kidneys ; Leukocytes (neutrophilic) ; Mice ; Overdose ; Rarefaction ; Renal failure ; Treg ; Vitamin B</subject><ispartof>The Journal of pathology, 2018-10, Vol.246 (2), p.191-204</ispartof><rights>Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley &amp; Sons, Ltd.</rights><rights>This article is protected by copyright. All rights reserved.</rights><rights>Copyright © 2018 Pathological Society of Great Britain and Ireland</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3532-d35790560619293b1411b08fd9fe87ce9bca56b7b60212a6dd733a401c8230b93</citedby><cites>FETCH-LOGICAL-c3532-d35790560619293b1411b08fd9fe87ce9bca56b7b60212a6dd733a401c8230b93</cites><orcidid>0000-0003-2718-3591</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29984403$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>González‐Guerrero, Cristian</creatorcontrib><creatorcontrib>Morgado‐Pascual, José Luis</creatorcontrib><creatorcontrib>Cannata‐Ortiz, Pablo</creatorcontrib><creatorcontrib>Ramos‐Barron, María Angeles</creatorcontrib><creatorcontrib>Gómez‐Alamillo, Carlos</creatorcontrib><creatorcontrib>Arias, Manuel</creatorcontrib><creatorcontrib>Mezzano, Sergio</creatorcontrib><creatorcontrib>Egido, Jesús</creatorcontrib><creatorcontrib>Ruiz‐Ortega, Marta</creatorcontrib><creatorcontrib>Ortiz, Alberto</creatorcontrib><creatorcontrib>Ramos, Adrián M</creatorcontrib><title>CCL20 blockade increases the severity of nephrotoxic folic acid‐induced acute kidney injury</title><title>The Journal of pathology</title><addtitle>J Pathol</addtitle><description>The chemokine CCL20 activates the CCR6 receptor and has been implicated in the pathogenesis of glomerular injury. However, it is unknown whether it contributes to acute kidney injury (AKI). We identified CCL20 as upregulated in a systems biology strategy combining transcriptomics of kidney tissue from experimental toxic folic acid‐induced AKI and from stressed cultured tubular cells and have explored the expression and function of CCL20 in experimental and clinical AKI. CCL20 upregulation was confirmed in three models of kidney injury induced by a folic acid overdose, cisplatin or unilateral ureteral obstruction. In injured kidneys, CCL20 was expressed by tubular, endothelial, and interstitial cells, and was also upregulated in human kidneys with AKI. Urinary CCL20 was increased in human AKI and was associated with severity. The function of CCL20 in nephrotoxic folic acid‐induced AKI was assessed by using neutralising anti‐CCL20 antibodies or CCR6‐deficient mice. CCL20/CCR6 targeting increased the severity of kidney failure and mortality. This was associated with more severe histological injury, nephrocalcinosis, capillary rarefaction, and fibrosis, as well as higher expression of tubular injury‐associated genes. Surprisingly, mice with CCL20 blockade had a lower tubular proliferative response and a higher number of cells in the G2/M phase, suggesting impaired repair mechanisms. This may be related to a lower influx of Tregs, despite a milder inflammatory response in terms of chemokine expression and infiltration by IL‐17+ cells and neutrophils. In conclusion, CCL20 has a nephroprotective role during AKI, both by decreasing tissue injury and by facilitating repair. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley &amp; Sons, Ltd.</description><subject>Acids</subject><subject>acute kidney injury</subject><subject>Animal models</subject><subject>calcification</subject><subject>Calcinosis</subject><subject>CCL20</subject><subject>CCL20 protein</subject><subject>CCR6</subject><subject>CCR6 protein</subject><subject>chemokine</subject><subject>Chemokines</subject><subject>Cisplatin</subject><subject>Fibrosis</subject><subject>Folic acid</subject><subject>Inflammation</subject><subject>Inflammatory response</subject><subject>Interstitial cells</subject><subject>Kidney diseases</subject><subject>Kidneys</subject><subject>Leukocytes (neutrophilic)</subject><subject>Mice</subject><subject>Overdose</subject><subject>Rarefaction</subject><subject>Renal failure</subject><subject>Treg</subject><subject>Vitamin B</subject><issn>0022-3417</issn><issn>1096-9896</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kL9OwzAQhy0EoqUw8AIoEhNDytnOP49VBRSpEgxlRJFjX9S0aRLsBMjGI_CMPAkuLWwsdzrdd99JP0LOKYwpALtuZLsch5SzAzKkICJfJCI6JEO3Yz4PaDwgJ9auAECIMDwmAyZEEgTAh-R5Op0z8LKyVmup0SsqZVBatF67RM_iK5qi7b069ypslqZu6_dCeXlduipVob8-PotKdwq1G7sWvXWhK-ydZ9WZ_pQc5bK0eLbvI_J0e7OYzvz5w939dDL3FQ858zUPYwFhBBEVTPCMBpRmkORa5JjECkWmZBhlcRYBo0xGWsecywCoShiHTPARudx5G1O_dGjbdFV3pnIvU0YpMHcHoaOudpQytbUG87QxxUaaPqWQboNMt0Gm2yAde7E3dtkG9R_5m5wDrnfAW1Fi_78pfZwsZj_Kb3xLfTo</recordid><startdate>201810</startdate><enddate>201810</enddate><creator>González‐Guerrero, Cristian</creator><creator>Morgado‐Pascual, José Luis</creator><creator>Cannata‐Ortiz, Pablo</creator><creator>Ramos‐Barron, María Angeles</creator><creator>Gómez‐Alamillo, Carlos</creator><creator>Arias, Manuel</creator><creator>Mezzano, Sergio</creator><creator>Egido, Jesús</creator><creator>Ruiz‐Ortega, Marta</creator><creator>Ortiz, Alberto</creator><creator>Ramos, Adrián M</creator><general>John Wiley &amp; Sons, Ltd</general><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><orcidid>https://orcid.org/0000-0003-2718-3591</orcidid></search><sort><creationdate>201810</creationdate><title>CCL20 blockade increases the severity of nephrotoxic folic acid‐induced acute kidney injury</title><author>González‐Guerrero, Cristian ; Morgado‐Pascual, José Luis ; Cannata‐Ortiz, Pablo ; Ramos‐Barron, María Angeles ; Gómez‐Alamillo, Carlos ; Arias, Manuel ; Mezzano, Sergio ; Egido, Jesús ; Ruiz‐Ortega, Marta ; Ortiz, Alberto ; Ramos, Adrián M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3532-d35790560619293b1411b08fd9fe87ce9bca56b7b60212a6dd733a401c8230b93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Acids</topic><topic>acute kidney injury</topic><topic>Animal models</topic><topic>calcification</topic><topic>Calcinosis</topic><topic>CCL20</topic><topic>CCL20 protein</topic><topic>CCR6</topic><topic>CCR6 protein</topic><topic>chemokine</topic><topic>Chemokines</topic><topic>Cisplatin</topic><topic>Fibrosis</topic><topic>Folic acid</topic><topic>Inflammation</topic><topic>Inflammatory response</topic><topic>Interstitial cells</topic><topic>Kidney diseases</topic><topic>Kidneys</topic><topic>Leukocytes (neutrophilic)</topic><topic>Mice</topic><topic>Overdose</topic><topic>Rarefaction</topic><topic>Renal failure</topic><topic>Treg</topic><topic>Vitamin B</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>González‐Guerrero, Cristian</creatorcontrib><creatorcontrib>Morgado‐Pascual, José Luis</creatorcontrib><creatorcontrib>Cannata‐Ortiz, Pablo</creatorcontrib><creatorcontrib>Ramos‐Barron, María Angeles</creatorcontrib><creatorcontrib>Gómez‐Alamillo, Carlos</creatorcontrib><creatorcontrib>Arias, Manuel</creatorcontrib><creatorcontrib>Mezzano, Sergio</creatorcontrib><creatorcontrib>Egido, Jesús</creatorcontrib><creatorcontrib>Ruiz‐Ortega, Marta</creatorcontrib><creatorcontrib>Ortiz, Alberto</creatorcontrib><creatorcontrib>Ramos, Adrián M</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>The Journal of pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>González‐Guerrero, Cristian</au><au>Morgado‐Pascual, José Luis</au><au>Cannata‐Ortiz, Pablo</au><au>Ramos‐Barron, María Angeles</au><au>Gómez‐Alamillo, Carlos</au><au>Arias, Manuel</au><au>Mezzano, Sergio</au><au>Egido, Jesús</au><au>Ruiz‐Ortega, Marta</au><au>Ortiz, Alberto</au><au>Ramos, Adrián M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CCL20 blockade increases the severity of nephrotoxic folic acid‐induced acute kidney injury</atitle><jtitle>The Journal of pathology</jtitle><addtitle>J Pathol</addtitle><date>2018-10</date><risdate>2018</risdate><volume>246</volume><issue>2</issue><spage>191</spage><epage>204</epage><pages>191-204</pages><issn>0022-3417</issn><eissn>1096-9896</eissn><abstract>The chemokine CCL20 activates the CCR6 receptor and has been implicated in the pathogenesis of glomerular injury. However, it is unknown whether it contributes to acute kidney injury (AKI). We identified CCL20 as upregulated in a systems biology strategy combining transcriptomics of kidney tissue from experimental toxic folic acid‐induced AKI and from stressed cultured tubular cells and have explored the expression and function of CCL20 in experimental and clinical AKI. CCL20 upregulation was confirmed in three models of kidney injury induced by a folic acid overdose, cisplatin or unilateral ureteral obstruction. In injured kidneys, CCL20 was expressed by tubular, endothelial, and interstitial cells, and was also upregulated in human kidneys with AKI. Urinary CCL20 was increased in human AKI and was associated with severity. The function of CCL20 in nephrotoxic folic acid‐induced AKI was assessed by using neutralising anti‐CCL20 antibodies or CCR6‐deficient mice. CCL20/CCR6 targeting increased the severity of kidney failure and mortality. This was associated with more severe histological injury, nephrocalcinosis, capillary rarefaction, and fibrosis, as well as higher expression of tubular injury‐associated genes. Surprisingly, mice with CCL20 blockade had a lower tubular proliferative response and a higher number of cells in the G2/M phase, suggesting impaired repair mechanisms. This may be related to a lower influx of Tregs, despite a milder inflammatory response in terms of chemokine expression and infiltration by IL‐17+ cells and neutrophils. In conclusion, CCL20 has a nephroprotective role during AKI, both by decreasing tissue injury and by facilitating repair. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley &amp; Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley &amp; Sons, Ltd</pub><pmid>29984403</pmid><doi>10.1002/path.5132</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0003-2718-3591</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0022-3417
ispartof The Journal of pathology, 2018-10, Vol.246 (2), p.191-204
issn 0022-3417
1096-9896
language eng
recordid cdi_proquest_journals_2110260205
source Wiley-Blackwell Read & Publish Collection
subjects Acids
acute kidney injury
Animal models
calcification
Calcinosis
CCL20
CCL20 protein
CCR6
CCR6 protein
chemokine
Chemokines
Cisplatin
Fibrosis
Folic acid
Inflammation
Inflammatory response
Interstitial cells
Kidney diseases
Kidneys
Leukocytes (neutrophilic)
Mice
Overdose
Rarefaction
Renal failure
Treg
Vitamin B
title CCL20 blockade increases the severity of nephrotoxic folic acid‐induced acute kidney injury
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T23%3A42%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CCL20%20blockade%20increases%20the%20severity%20of%20nephrotoxic%20folic%20acid%E2%80%90induced%20acute%20kidney%20injury&rft.jtitle=The%20Journal%20of%20pathology&rft.au=Gonz%C3%A1lez%E2%80%90Guerrero,%20Cristian&rft.date=2018-10&rft.volume=246&rft.issue=2&rft.spage=191&rft.epage=204&rft.pages=191-204&rft.issn=0022-3417&rft.eissn=1096-9896&rft_id=info:doi/10.1002/path.5132&rft_dat=%3Cproquest_cross%3E2110260205%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3532-d35790560619293b1411b08fd9fe87ce9bca56b7b60212a6dd733a401c8230b93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2110260205&rft_id=info:pmid/29984403&rfr_iscdi=true